Anticorps Recombinant de lapin anti-NCOA4

NCOA4 Recombinant Antibody for IF/ICC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

IF/ICC

Conjugaison

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

240169H7

N° de cat : CL488-83394-4

Synonymes

ELE1, ARA70, Androgen receptor-associated protein of 70 kDa, 70 kDa AR-activator, 70 kDa AR activator

---

Galerie de données de validation

• 

  IF Staining of HepG2 using CL488-83394-4

  Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using CoraLite® Plus 488 NCOA4 antibody (CL488-83394-4, Clone: 240169H7 ) at dilution of 1:200.

---

Applications testées

• Résultats positifs en IF/ICC: cellules HepG2,

Dilution recommandée

• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

CL488-83394-4 cible NCOA4 dans les applications de IF/ICC et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: NCOA4 Protéine recombinante Ag15277
• Nom complet: nuclear receptor coactivator 4
• Masse moléculaire calculée: 70 kDa
• Poids moléculaire observé: 70-73 kDa
• Numéro d’acquisition GenBank: BC012736
• Symbole du gène: NCOA4
• Identification du gène (NCBI): 8031
• Conjugaison: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Conditions de stockage: Stocker à -20 °C. Éviter toute exposition à la lumière. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Nuclear receptor coactivator 4 (NCOA4) also named androgen receptor (AR) coactivator ARA70, RFG and ELE1, is a putative co-activator that specifically enhances the activity of the androgen receptor. In human thyroid carcinomas, the Ret proto-oncogene fuses to ARA70 to form Ret/PTC3 by an intrachromosomal inversion of chromosome 10 in vivo. ARA70a can function as a ligand-enhanced co-activator of PPARg in adipocytes. However, PPARg-ARA70 transactivation can be squelched by AR, which suggests cross talk between PPARg- and AR-mediated response. ARA70a has no intrinsic transcription activation domain or histone acetyltransferase activity, but it interacts with histone acetyltransferase, p/CAF, CBP and p300/CBP-associated factors, and the basal transcription factor TFIIB. The interaction between ARA70 and AR occurs through the ligand-binding domain. The presence of ARA70 can enhance the androgenic activity of 17-b Estradiol (E2) and antiandrogens toward AR. ARA70 may be involved in prostate carcinogenesis and ovarian cancer and may serve as a key mediator of estrogen-androgen synergism.

{{ptg:RelatedPrimaryAntibodies}}